OR WAIT null SECS
Jolie is the Content Specialist for Ophthalmology Times. She can be reached at email@example.com.
Here's a snapshot of what got attendees most excited at ASCRS 2016.
- Abbott (@AbbottNews) May 9, 2016
The company reported that the trial for the new IOL met its primary endpoints for improved near and intermediate vision.
"Many people with cataracts are asking for an option that will help them perform near activities like reading, use their computers and tablets at intermediate distance, as well as see objects that are far away," said Jason Jones, MD, investigator on the study. "The data from this study showed that patients who received the Symfony lens were more likely to achieve improved intermediate and near vision, while maintaining similar distance vision compared with patients who received a standard IOL."
- Kristen (@KHingenito) May 9, 2016
David R. Brear, MD, from Culpeper, VA won a Tesla Model S by entering into the ASCRS drawing. We don’t think he’ll mind that long drive home.
- Dr Daya Sharma (@DrDayaSharma) May 9, 2016
During his talk, ‘Dark Side of the Moon: Intracranial Pressure in Glaucoma’ John P. Berdahl, MD, explained how astronauts returning from space hold some key clues about glaucoma, which he called a two-pressure disease. To read more about his talk, click here.
- Erin Masercola (@MasercolaWrites) May 8, 2016
With 364 participants at the starting line at the 4th annual run in New Orleans, the ASCRS Foundation raised over $12,000, bringing their total from the past four years to $81,000.
- Ophthalmology Times (@OphthTimes) May 7, 2016
The collaborative app is meant to streamline the workflow of cataract surgeons. Pilot testing is expected to begin late 2016 and will be available on iPhones and iPads. Click here to learn more.
Cosmetic iris implants like NewColorIris & BrightOcular would *never* be approved in places w good regulation like US, UK or Australia
- Dr Daya Sharma (@DrDayaSharma) May 6, 2016
Patients are travelling abroad to have procedures done, despite the lack of regulation and permanant consequences. It is the responsibility of the surgeon to fully explain the dangers to patients and encourage prompt removal. To read more, click here.
- MichaelJohnson (@mjohnsp) May 7, 2016
OWL panel members presented a talk on diversity, explaining their desire to reach out not only to women, but to ophthalmic profressionals with a wide range of cultural and ethnic backgrounds.
- Pascale (@PascaleCom) May 8, 2016
While some booths took advantage of the meeting occuring on Mother's Day by giving out roses to all the women, one booth allowed attendees to pose for a photo to celebrate the day.
- ASCRS (@ASCRStweets) May 9, 2016
Congrats to Shin Yamane, MD of Yokohama, Japan, the 2016 Grand Prize winner at the ASCRS Film Festival Awards! The video was titled: Transconjunctival Intrascleral IOL Fixation with Double-Needle Technique.
- Imprimis Pharma (@ImprimisPharma) May 5, 2016
The patent-pending melt, containing midazolam, ketamine, and ondansetron (IV Free MKO Melt, Imprimis) allows for consistent dosing which is gaining in popularity due to its ease of administration. The company says this formulation, which eliminates the need for intravenous sedation medication, can reduce the need for additional staff to assist with the procedure.
- Rob Melendez,MD,MBA (@DrRobMelendez) May 8, 2016
In honor of the 2016 Rio De Janeiro Summer Olympics, the ASCRS committee orchestrated a 90-minute symposium on managing complicated cataract cases. Moderator David F. Chang, MD, said the event is a "must-see" in which surgeons from 14 countries present their best video teaching cases in rapid fire succession.
The four Olympic events are:
Ophthalmologists have had mixed feelings about the timing of the Olympic Games and the Zika virus. Read more and join the conversation.
- Dr Daya Sharma (@DrDayaSharma) May 7, 2016
- Dr Daya Sharma (@DrDayaSharma) May 7, 2016
Dr. Stulting said the constant dilemma surgeons face is classifying corneal topography maps. "Even the best of us have a hard time judging these images," he said. "But why is our risk system failing today? RSB is increasing, but FFKC is decreasing. Corneal thickness is also decreasing. The mean patient age is decreasing. We're still operating on young patients and the elimination of other risk factors are making age a much more relevant factor."
To read more about his lecture, click here.
- ASCRS (@ASCRStweets) May 7, 2016
Dr. Kim, also known as DJ Special K, was recently featured in an article about how he juggles DJing with his hectic schedule as a surgeon. To learn more, click here. Dr. Kim also spins his music at a private event every year during ASCRS.
- Ophthalmology Times (@OphthTimes) May 6, 2016
Lumenis releases data from their clinical trial studying 40 patients receiving 3 treatments for dry eye caused by Meibomian Gland Dynsfunction (MGD). The study included examinations of tear break-up time, SPEED questionaire scores, and tear osmolarity.
- Fast-Track Marketing (@FTMarketing) May 11, 2016
The New Orleans fun didn't stop at the end of sessions!
- ASCRS (@ASCRStweets) May 6, 2016
See you next year in Los Angeles!
Click here for 10 things you may have missed at ARVO 2016